SGSigurður Guðmundsson

Sigurður Guðmundsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sigurður Guðmundsson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Frank Espersen

    Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2

    1 shared publication
  • Helga Erlendsdottir

    Departments of Microbiology, Landspitalinn (University Hospital), Reykjavík, Iceland

    1 shared publication
  • Inga Odenholt

    Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2

    1 shared publication
  • Jenny Dahl Knudsen

    Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2

    1 shared publication
  • Karl G. Kristinsson

    Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2

    1 shared publication
  • Kurt Fuursted

    Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2

    1 shared publication

Latest Publications

    • 1 November 2004
      • Vol. 90  (11) , 735-6

    [Vioxx - What can we learn? [Editorial].].

    by Sigurður Guðmundsson

    • 1 March 2004
      • Vol. 90  (3) , 203-4

    [Disease prevention - curse or blessing? [Editorial].].

    by Sigurður Guðmundsson

    • 1 October 2002
      • Vol. 88  (10) , 713-4

    [Colorectal cancer screening [Editorial].].

    by Sigurður Guðmundsson

    • 1 January 2002
      • Vol. 88  (1) , 7

    [New year's thoughts on health care [Editorial].].

    by Sigurður Guðmundsson

  • Open Access

    Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models

    by Helga Erlendsdottir, Jenny Dahl Knudsen, Inga Odenholt, Otto Cars, Frank Espersen, Niels Frimodt-Møller, Kurt Fuursted, Karl G. Kristinsson, Sigurdur Gudmundsson

    Clinical and animal studies indicate that with optimal dosing, penicillin may still be effective against penicillin-nonsusceptible pneumococci (PNSP). The present study examined whether the same strains of penicillin-susceptible pneumococci (PSP) and PNSP differed in their pharmacodynamic responses to penicillin by using comparable penicillin dosing regimens in four animal models: peritonitis, pneumonia, and thigh infection in mice and tissue cage infection in rabbits. Two multidrug-resistant isolates of Streptococcus pneumoniae type 6B were used, one for which the penicillin MIC was 0.016 μg/ml and the other for which the penicillin MIC was 1.0 μg/ml. Two additional strains of PNSP were studied in the rabbit. The animals were treated with five different penicillin regimens resulting in different maximum concentrations of drugs in serum ( C max s) and times that the concentrations were greater than the MIC ( T >MIC s). The endpoints were bacterial viability counts after 6 h of treatment in the mice and 24 h of treatment in the rabbits. Similar pharmacodynamic effects were observed in all models. In the mouse models bactericidal activity depended on the T >MIC and to a lesser extent on the C max /MIC and the generation time but not on the area under the concentration-time curve (AUC)/MIC. Maximal bactericidal activities were similar for both PSP and PNSP, being the highest in the peritoneum and blood (∼6 log 10 CFU/ml), followed by the thigh (∼3 log 10 CFU/thigh), and being the lowest in the lung (∼1 log 10 CFU/lung). In the rabbit model the maximal effect was ∼6 log 10 CFU/ml after 24 h. In the mouse models bactericidal activity became marked when T >MIC was ≥65% of the experimental time and C max was ≥15 times the MIC, and in the rabbit model bactericidal activity became marked when T >MIC was ≥35%, C max was ≥5 times the MIC, and the AUC at 24 h/MIC exceeded 25. By optimization of the C max /MIC ratio and T >MIC , the MIC of penicillin for pneumococci can be used to guide therapy and maximize therapeutic efficacy in nonmeningeal infections caused by PNSP.